**Appendix Table O1. Characteristics of eligible studies: NSAIDs in adults with normal cognition**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Study**  **Design Country**  **RoB** | **N=** | **Population**  **Inclusion**  **Age (mean)**  **Sex (% female)**  **Race (% White)**  **Education (mean years)**  **Baseline Cognition** | **Intervention** | **Comparison** | **Outcome**  **Timing** | **Outcome**  **Domain [Instrument]** |
| ADAPT Group[1-5](#_ENREF_1)RCT  USA  10 years[4](#_ENREF_4)  High  8 years  Medium  5 years  Medium  4 years  2008: Medium  2007: Medium | 10 years  1689  8 years  2117  5 years  2071  4 years  2528 | Adults aged 70+ with normal cognition and at least 1 first-degree relative with AD-like dementia  **Age** (median)  70-74: 55%  75-79: 32%  80-84: 11%  85+: 2%  **Sex** 46%  **Race**  White: 97%  Black: 2%  Hispanic: 1%  **Education**  Less than high school: 4%  High school degree: 20%  College, no degree: 27%  College degree: 19%  Postgrad: 30%  **Baseline cognition** (median)  Adjusted 3MS: 95.0 | Celecoxib (200 mg BID) or naproxen (220 mg BID) | Placebo | 10 years  8 years1  5 years2  4 years3, 4 | **10 years**  Brief Cognitive Test Performance [3MS]  Multidomain Neuropsychological Test Performance [Composite: HVLT-R, Informant-Rated Dementia Severity Rating Scale, Digit Span, Naming Supermarkets, RBMT]  Executive/Attention/Processing Speed [Digit Span]  Memory [HVLT] [RBMT]  Language [Generative Verbal Fluency]  **8 years**  Diagnosis [Alzheimer’s Disease]  **5 years**  Diagnosis [Alzheimer’s Disease] Biomarker [CSF tau : Ab1-42]  **4 years**  Diagnosis [Alzheimer’s Disease]  Brief Cognitive Test Performance [3MS]  Multidomain Neuropsychological Test Performance [Composite: HVLT-R, Informant-Rated Dementia Severity Rating Scale, Digit Span, Naming Supermarkets, RBMT]  Executive/Attention/Processing Speed [Digit Span]  Memory [HVLT] [RBMT] |
| Small, 2008[6](#_ENREF_6)  RCT  USA  High | 88 | Middle-aged and older volunteers with normal cognition and self-reported age-related memory complaints  **Age** 58  **Sex** 38%  **Race** NR  **Education** (mean years)15  **Baseline cognition** (median)  MMSE: 29.2 | Celecoxib 200 mg or 400 mg QD | Placebo | 1.5 years | Executive/Attention/Processing Speed [TMT A] [TMT B] [DSST] [Stroop Interference Kaplan Version] [F.A.S. Letter Fluency Test]  Memory [Buschke Selective Reminding Test Total And Delayed Recall] [WMS Verbal Paired Associations] [BVRT]  Language [BNT] [Animal Naming Test]  Visuospatial [WAIS-III Block Design Test] [RCFT]] |
| Kang, 2007[7](#_ENREF_7)  RCT  USA  Medium | 6377 | Normal cognition, women aged 65+ participating in healthy study  **Age** 72  **Sex** 100%  **Race** NR  **Education**  Licensed vocational or registered nurse/associates degree: 67%  Bachelors/masters/doctorate degree: 33%  **Baseline cognition**  TICS: 34 | Aspirin (100 mg QAD) | Placebo | 10 years | Brief Cognitive Test Performance [TICS]  Multidomain Neuropsychological Test Performance [Composite: TICS, Category Fluency, 10 Words List Immediate And Delayed Recall, EBMT] Memory [Composite: 10 Words List Immediate And Delayed Recall, EBMT] |

3MS=Modified Mini-Mental State Examination; BID=twice daily; EBMT=East Boston Memory Test; mg=milligrams; n=sample size; NP=Neuropsychological; NR=not reported; QAD=every other day; QD=every day; SD=standard deviation; RCT=randomized controlled trial; RBMT= Rivermead Behavioral Memory Test; RCFT=Rey-Osterrieth Complex Figure Test; USA=United States; WAIS=Wechsler Adult Intelligence Scale; WMS=Wechsler Memory Scale